左旋多巴/ 卡比多巴联合恩他卡朋治疗帕金森病的临床研究

目的:观察左旋多巴/卡比多巴联合恩他卡朋(levodopa/carbidopa combined with entacapone,LC+E)治疗帕金森病(Parkinson's disease,PD)的临床效果。方法:选择我院2013年1月~2014年6月收治的112例PD患者,随机分为两组。其中对照组52例采用左旋多巴/卡比多巴(LC)治疗,观察组60例采用左旋多巴/卡比多巴联合恩他卡朋(LC+E)治疗。观察并比较两组治疗前后帕金森病评分量表(Unified Parkinson's Disease Rating Scale,UPDRS)的评分变化情况。结果:与治疗前比较,治疗后两组UPDRS-II日常生活能力评分,UPDRS-III运动能力评分显著下降,而UPDRS-VI SCHWABENGLAND日常活动能力评分显著上升,差异有统计学意义(P0.05);观察组各项变化情况比对照组明显,差异有统计学意义(P0.05)。两组UPDRS-I精神、行为、情绪和Hoehn与Yahr分级均无显著改善,差异无统计学意义(P0.05)。结论:左旋多巴/卡比多巴联合恩他卡朋可明显缓解PD症状,疗效优于左旋多巴/卡比多巴治疗,且安全性高,值得临床推广。

A Clinical Study of Levodopa/carbidopa Combined with Entacapone inParkinson's Disease

Objective:To investigate the clinical effect of levodopa/carbidopa combined with entacapone (LC+E) in the treatmentof Parkinson''s disease (PD).Methods:112 patients with PD who were treated in our hospital from January 2013 to June 2014 were selectedand randomly divided into two groups. The patients in the control group (n=52) were treated with levodopa/carbidopa (LC), whilethe patients in the observation group (n=60) were treated with levodopa/carbidopa combined with entacapone (LC+E). Then the changesofUnified Parkinson''sDisease RatingScale (UPDRS) inthe twogroups were observedand comparedbefore and after the treatment.Results:After treatment, UPDRS-II of ability of daily life, UPDRS-III of motion examination and UPDRS-IV of complications in the two groupssignificantly decreased, and UPDRS-VI of SCHWAB&ENGLAND scale of the ability of daily life increased (P<0.05); The changes ofthe observation group were significantly than those of the control group, and the differences were statistically significant (P<0.05). Therewas no significant difference about the UPDRS-I of mental, behavioral and emotional and UPDRS-V of the modify Hoehn and Yahrclassification between the two groups (P>0.05).Conclusion:LC+E can significantly relieve the symptoms of PD, which is much betterthan that in LC. And, it has a higher safety. It is worth the clinical promotion.